Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Reglan Side Effect Tardive Dyskinesia May Qualify Metoclopramide Users for Lawsuit

(EMAILWIRE.COM, March 08, 2011 ) New York, NY – Patients who developed tardive dyskinesia as a side effect of Reglan may have legal recourse. Reglan and other metoclopramide drugs have been linked to this neurological disorder, and users who have been diagnosed with tardive dyskinesia may be able to file a lawsuit to recover compensation for medical bills, pain and suffering and other damages resulting from their condition. Patients pursuing Reglan litigation should keep in mind, however, that there is a time limit for filing Reglan tardive dyskinesia cases; failure to file a claim within a certain time period will bar the patient from ever recovering financial compensation for their Reglan side effects. Therefore, if you have developed this Reglan neurological side effect, it’s important to learn your legal rights today. Fill out the free case evaluation form at http://www.classaction.org/reglan.html to find out if you can participate in a Reglan tardive dyskinesia lawsuit.

Tardive dyskinesia is a neurological syndrome which has been associated with the long-term use of Reglan and other drugs containing metoclopramide, a drug used to treat gastrointestinal disorders. Tardive dyskinesia is a condition characterized by repetitive, purposeless and involuntary movements of the body. Symptoms of Reglan tardive dyskinesia may include the following: rapid eye blinking; grimacing; lip smacking; tongue protrusion; and rapid movements of the trunk, arms and legs. No standard treatment exists for tardive dyskinesia, though stopping metoclopramide treatment may help some patients.

In February 2009, Reglan tardive dyskinesia was of such a concern that the FDA required a black box warning for metoclopramide to alert patients to the risk of the drugÂ’s long-term or high-dose use. Reglan was only approved for short term treatment, typically between four and 12 weeks, for acid reflux, gastroesophageal reflux disease (GERD) and diabetic gastroparesis; however, Reglan may have been prescribed to patients for longer than 12 weeks, which is against FDA recommendations. According to the FDA, chronic use of Reglan or other metoclopramide-containing drugs has been linked to tardive dyskinesia, a condition producing symptoms which are rarely reversible.

If you or a loved one developed Reglan tardive dyskinesia, you may be able to take legal action to recover compensation for medical bills, loss of earning capacity and other damages. To find out if you can participate in a Reglan lawsuit, visit Class Action.org today and complete the free case review form. This online legal consultation is provided at no cost, courtesy of the Reglan litigation attorneys working with the site.

About Class Action.org

Class Action.org is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class Action.org keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit http://www.classaction.org today for a no cost, no obligation case evaluation and information about your consumer rights.


ClassAction.org
Tara Nagel
800-449-1970
pressrelease@lawyercentral.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC